Display options
Cite
Sagir A, Glaubach B, Sahin K, et al. Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infect Dis Ther. 2015;4(3):355-64doi: 10.1007/s40121-015-0073-y.
Sagir, A., Glaubach, B., Sahin, K., Graf, D., Erhardt, A., Oette, M., & Häussinger, D. (2015). Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infectious diseases and therapy, 4(3), 355-64. https://doi.org/10.1007/s40121-015-0073-y
Sagir, Abdurrahman, et al. "Transient Elastography for the Detection of Liver Damage in Patients with HIV." Infectious diseases and therapy vol. 4,3 (2015): 355-64. doi: https://doi.org/10.1007/s40121-015-0073-y
Sagir A, Glaubach B, Sahin K, Graf D, Erhardt A, Oette M, Häussinger D. Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infect Dis Ther. 2015 Sep;4(3):355-64. doi: 10.1007/s40121-015-0073-y. Epub 2015 Jul 05. PMID: 26143457; PMCID: PMC4575292.
Copy Download .nbib Format: NLM
Share it on

Infect Dis Ther. 2015 Sep;4(3):355-64. doi: 10.1007/s40121-015-0073-y. Epub 2015 Jul 05.

Transient Elastography for the Detection of Liver Damage in Patients with HIV.

Infectious diseases and therapy

Abdurrahman Sagir, Birgit Glaubach, Kurtulus Sahin, Dirk Graf, Andreas Erhardt, Mark Oette, Dieter Häussinger

Affiliations

  1. Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany. [email protected].
  2. Bethesda Krankenhaus Duisburg, Duisburg, Germany. [email protected].
  3. Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany.
  4. Institut für Medizinische Statistik, Informatik und Epidemiologie, Universität zu Köln, Cologne, Germany.
  5. Augustinerinnen Hospital, Cologne, Germany.

PMID: 26143457 PMCID: PMC4575292 DOI: 10.1007/s40121-015-0073-y

Abstract

INTRODUCTION: Highly active antiretroviral therapy (HAART) is effective and well tolerated, but hepatotoxicity is relatively common. Different non-invasive methods are available for detecting liver fibrosis in patients with chronic liver disease.

METHODS: Patients who were HIV positive and who had given their informed consent were included in this cross-sectional study. Transient elastography [FibroScan(®) (FS); Echosens], serum hyaluronic acid (HA), Hepascore (HS), Fibrosis-4 (FIB-4), and aspartate aminotransferase to platelet ratio index (APRI) were used to detect liver fibrosis in the patients. The agreement between FS and the other methods was evaluated. To observe the hepatotoxicity of HAART, patients with chronic viral hepatitis B or C were excluded by detection of hepatitis B surface antigens and hepatitis C virus antibodies. Patients with chronic alcohol intake were excluded by measuring carbohydrate-deficient transferrin (CDT). FS correlation with the duration of therapy with protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI) was evaluated.

RESULTS: Overall, 203 patients were included in the study. The agreement between the different tests ranged from 64% to 77%: FS vs. HA, 72%; FS vs. APRI, 74%; FS vs. HS, 77%; and FS vs. FIB-4, 64%. After excluding patients with chronic hepatitis B or C and elevated CDT, 153 patients remained for studying the hepatotoxicity of HAART. A significant correlation of FS with the duration of medication intake was observed for PIs (P = 0.026; r = 0.18). NRTI and NNRTI therapy duration did not correlate with FS.

CONCLUSIONS: The agreement between FS and other tests ranged from 64% to 77%. A significant correlation was found between liver stiffness and the duration of therapy with PIs, which underlines the known hepatotoxicity of this substance group.

FUNDING: Heinz-Ansmann Foundation.

Keywords: FibroScan®; HIV; Hepatotoxicity; Highly active antiretroviral therapy (HAART); Liver; Transient elastography

References

  1. Gut. 2006 Mar;55(3):403-8 - PubMed
  2. Eur J Gastroenterol Hepatol. 2008 Dec;20(12 ):1194-204 - PubMed
  3. Liver Int. 2013 Jan;33(1):79-85 - PubMed
  4. Gastroenterology. 2005 Feb;128(2):343-50 - PubMed
  5. Clin Chem. 2005 Oct;51(10):1867-73 - PubMed
  6. Ultrasound Med Biol. 2003 Dec;29(12 ):1705-13 - PubMed
  7. J Acquir Immune Defic Syndr. 2006 May;42(1):52-60 - PubMed
  8. AIDS Rev. 2003 Jan-Mar;5(1):36-43 - PubMed
  9. J Hepatol. 2006;44(1 Suppl):S132-9 - PubMed
  10. Curr Pharm Des. 2005;11(28):3697-710 - PubMed
  11. Curr Opin HIV AIDS. 2007 Nov;2(6):466-73 - PubMed
  12. J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 - PubMed
  13. Curr Opin HIV AIDS. 2008 Nov;3(6):653-9 - PubMed
  14. J HIV Ther. 2003 Nov;8(4):96-100 - PubMed
  15. J Infect Dis. 2008 May 15;197 Suppl 3:S279-93 - PubMed
  16. AIDS Rev. 2013 Jul-Sep;15(3):139-45 - PubMed
  17. BMC Infect Dis. 2005 Jul 14;5:58 - PubMed
  18. Hepatology. 2006 Jun;43(6):1317-25 - PubMed
  19. Hepatology. 2003 Aug;38(2):518-26 - PubMed
  20. Addiction. 2013 Sep;108(9):1579-89 - PubMed
  21. BMC Infect Dis. 2012 Nov 12;12:296 - PubMed
  22. N Engl J Med. 2001 Feb 15;344(7):495-500 - PubMed
  23. JAMA. 2000 Jan 5;283(1):74-80 - PubMed
  24. Dig Liver Dis. 2006 Jun;38(6):363-73 - PubMed
  25. J Hepatol. 2000 Mar;32(3):447-52 - PubMed
  26. Hepatology. 2008 Nov;48(5):1718-23 - PubMed
  27. J Infect Dis. 2002 Jul 1;186(1):23-31 - PubMed
  28. AIDS Patient Care STDS. 2007 Jul;21(7):469-78 - PubMed
  29. Hepatology. 2008 Feb;47(2):592-5 - PubMed
  30. Pharmacotherapy. 2002 Nov;22(11):1468-78 - PubMed
  31. Infection. 2013 Apr;41(2):545-51 - PubMed
  32. J Antimicrob Chemother. 2007 Sep;60(3):461-3 - PubMed
  33. Dtsch Med Wochenschr. 2006 Dec 8;131(49):2765-9 - PubMed
  34. Liver Int. 2009 Nov;29(10):1500-6 - PubMed
  35. World J Gastroenterol. 2009 May 28;15(20):2433-40 - PubMed
  36. Eur J Public Health. 2006 Dec;16(6):601-8 - PubMed

Publication Types